Vertex Pharmaceuticals climbs on positive interim data from IgAN phase 3 trial
Source: SeekingAlpha
2026-03-10 04:50:36 ET
More on Vertex Pharmaceuticals
- Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take
- Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade)
- Key deals this week: KORE, TopBuild, Equinix, PayPal and more
- Crispr Therapeutics gains amid takeover speculation
Read the full article on Seeking Alpha
For further details see:
Vertex Pharmaceuticals climbs on positive interim data from IgAN phase 3 trial
Vertex Pharmaceuticals Incorporated
NASDAQ: VRTX
VRTX Trading
-2.4% G/L:
$479.43 Last:
567,209 Volume:
$489.97 Open:
VRTX Latest News
March 09, 2026 04:02:00 pm
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
March 08, 2026 06:08:00 pm
Buying This 1 Biotech Stock Now Could Help Make You a Multimillionaire Retiree
VRTX Stock Data
$118,425,801,558
253,211,393
0.21%
875
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
